Legal & General Group Plc Raises Stock Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Legal & General Group Plc lifted its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 26.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 253,426 shares of the company's stock after acquiring an additional 53,458 shares during the period. Legal & General Group Plc owned approximately 0.06% of Recursion Pharmaceuticals worth $1,713,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Barclays PLC boosted its stake in Recursion Pharmaceuticals by 53.9% during the third quarter. Barclays PLC now owns 697,432 shares of the company's stock valued at $4,596,000 after buying an additional 244,278 shares during the period. Sanctuary Advisors LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $89,000. Franklin Resources Inc. lifted its stake in Recursion Pharmaceuticals by 58.9% during the third quarter. Franklin Resources Inc. now owns 18,963 shares of the company's stock worth $127,000 after purchasing an additional 7,027 shares during the last quarter. JPMorgan Chase & Co. lifted its stake in Recursion Pharmaceuticals by 6.1% during the third quarter. JPMorgan Chase & Co. now owns 1,176,191 shares of the company's stock worth $7,751,000 after purchasing an additional 67,464 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after purchasing an additional 4,948 shares during the last quarter. 89.06% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

RXRX has been the subject of several research analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Morgan Stanley lowered their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research report on Thursday, April 10th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Leerink Partners reduced their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a report on Friday, February 28th. Finally, KeyCorp reduced their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $8.20.

Recursion Pharmaceuticals Stock Performance

Shares of Recursion Pharmaceuticals stock traded down $0.10 during trading hours on Tuesday, reaching $5.74. 1,877,914 shares of the stock traded hands, compared to its average volume of 12,248,287. Recursion Pharmaceuticals, Inc. has a one year low of $3.79 and a one year high of $12.36. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -3.76 and a beta of 1.00. The company has a 50 day moving average price of $6.11 and a 200 day moving average price of $6.78.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.53) EPS for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to analysts' expectations of $19.04 million. During the same period in the prior year, the firm posted ($0.42) earnings per share. The firm's revenue for the quarter was down 57.8% on a year-over-year basis. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.